



Press Release

State of the art facility for ampoules opened STADA Group makes further investment in Serbian location

Bad Vilbel/Vršac, June 8, 2015 – STADA's Serbian subsidiary Hemofarm celebrated the opening of a state-of-the-art production and filling facility for ampoules in Vršac on Sunday, May 31, 2015. STADA has thus invested a total of approximately Euro 150 million in Serbia since the integration of the largest Serbian health company into the Group in 2006. The value of the new plant amounts to Euro 4.37 million.

"We are very proud of this new production facility with its equipment and technology of the highest international standard. We have thus once again strengthened one of our most important locations and our international competitiveness", says Hartmut Retzlaff, Chairman of the Executive Board at STADA. The opening of the new plant took place on the 55th anniversary of Hemofarm in the presence of the Serbian Prime Minister Aleksandar Vučić.

In the future, up to 75 million ampoules will be produced annually across a floor area of 600 square meters. They are not intended for the Serbian home market only, but will be mostly exported. All production steps, from manufacturing to packaging the solutions, are carried out on site through 50 highly qualified employees.

About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics producer in Germany. STADA is represented in more than 30 countries with approximately 50 subsidiaries worldwide. Branded products such as Grippostad and Ladival are among the highest selling in their product category in Germany. In financial year 2014, STADA achieved Group sales of Euro 2,062.2 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 431.9 million and adjusted net income of Euro 186.2 million. As of December 31, 2014, STADA employed 10,363 people worldwide.

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend



For additional information, please contact:

STADA Arzneimittel AG

Media Relations

Stadastraße 2–18

61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-165

Fax: +49 (0) 6101 603-215

E-mail: press@stada.de

Web: www.stada.de

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend